A New Milestone in the Treatment of Pediatric Low-Grade Gliomas

The ACNS1833 (NCT04166409) clinical trial evaluates the efficacy of Koselugo (selumetinib), a targeted therapy, in patients with pediatric low-grade gliomas. This Phase 3 study compares Koselugo to the existing standard chemotherapy regimen of carboplatin and vincristine, with the goal of improving progression-free survival. The study focuses on patients without BRAF V600E mutations and without neurofibromatosis type 1, aiming to implement precision medicine. The study began in January 2020 and is expected to be completed by December 2030.

Innovation and Differentiation of the MEK Inhibition Mechanism

Koselugo is a mitogen-activated protein kinase (MEK 1/2) inhibitor that blocks tumor cell growth pathways, effectively preventing abnormal cell division. In contrast, carboplatin, the comparator, is a platinum-based chemotherapy drug that interferes with DNA replication, and vincristine inhibits cell division to stop tumor growth. Koselugo selectively targets tumor cells, which is expected to significantly reduce the systemic toxicity and side effects associated with conventional chemotherapy. The introduction of an oral targeted therapy can fundamentally improve the quality of life for pediatric patients and their caregivers, who previously suffered from frequent intravenous administrations.

Addressing Unmet Needs and Transforming the Standard of Care

Pediatric low-grade gliomas account for approximately 30-40% of all pediatric central nervous system tumors, but existing chemotherapy regimens have been associated with permanent neurological damage or toxicity. If Koselugo demonstrates superiority in this non-inferiority trial, it will mark a historic turning point, replacing the current standard of care with a safer targeted therapy. By providing personalized treatment options, it will enhance the integration of precision diagnostics and treatment across the pediatric oncology field. This is expected to bring about significant changes in clinical practice by addressing unmet medical needs for which there were previously no treatment options.

Global Pharmaceutical Companies' Moves in a Fiercely Competitive Landscape

The pediatric neuro-oncology market is a dynamic field where global pharmaceutical companies are competing to expand their territories with innovative new drugs. Day One's tovorafenib (Ojemda) received accelerated FDA approval in April 2024, gaining a foothold in the market, and Novartis' Tapinar and Mekinist combination therapy has also established itself as a strong competitor. Koselugo has already received its first FDA approval in April 2020 for the treatment of pediatric patients with neurofibromatosis type 1 and expanded its indications to adult patients in 2025, accumulating strong data. The results of this trial will be a key factor in securing a competitive advantage for Koselugo in the pediatric first-line treatment market.

Joint Development through a Mega Deal and Financial Expectations

AstraZeneca and Merck entered into a strategic oncology co-development agreement in July 2017, with a total value of $8.5 billion. Merck paid an upfront payment of $1.6 billion, with milestone payments of $6.15 billion and option payments of $750 million upon regulatory and commercial success. The two companies share the development costs of Koselugo and the total profits generated after commercialization on a 50/50 basis, diversifying financial risks and sharing the benefits. If this Phase 3 trial is successful and indications are added, the annual revenue pipeline of both companies will be further strengthened, and they will be able to strengthen their market dominance in the area of pediatric rare diseases.